Enanta Pharmaceuticals Inc. Insider Trading

ENTA

Last 12 months

Insiders sold 183K and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. The last open-market buy by an executive or director was in Feb 2025.

Net open-market

−183K

0 buys · 9 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 7

executives and directors

Last open-market buy

Feb 2025

Feb 12, 2025

Get an email when ENTA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Dec 5, 2025	Kathleen S. Capps See Remarks	SoldNo plan	323	$14.23	5K	3.7%	Form 4
Dec 5, 2025	Harry R. Trout III See Remarks	SoldNo plan	542	$14.23	8K	3.2%	Form 4
Dec 5, 2025	Scott T. Rottinghaus Chief Medical Officer	SoldNo plan	798	$14.23	11K	3.5%	Form 4
Dec 5, 2025	Brendan Luu Chief Business Officer	SoldNo plan	1,394	$14.23	20K	3.5%	Form 4
Dec 5, 2025	Tara Lynn Kieffer Chief Product Strategy Officer	SoldNo plan	2,106	$14.23	30K	6.4%	Form 4
Dec 5, 2025	Yat Sun Or Chief Scientific Officer	SoldNo plan	2,390	$14.23	34K	0.6%	Form 4
Dec 5, 2025	Jay R. Luly President and CEO	SoldNo plan	4,743	$14.23	67K	0.5%	Form 4
Dec 2, 2025	Kathleen S. Capps See Remarks	SoldNo plan	207	$13.96	3K	2.3%	Form 4
Dec 2, 2025	Harry R. Trout III See Remarks	SoldNo plan	380	$13.96	5K	2.2%	Form 4
Feb 12, 2025	Jay R. Luly President and CEO	Bought	45,000	$5.69	256K	5.6%	Form 4
Dec 6, 2024	Tara Lynn Kieffer Chief Product Strategy Officer	Sold10b5-1 plan	2,283	$8.06	18K	7.2%	Form 4
Dec 6, 2024	Brendan Luu Chief Business Officer	Sold10b5-1 plan	2,283	$8.06	18K	6.0%	Form 4
Dec 6, 2024	Scott T. Rottinghaus Chief Medical Officer	Sold10b5-1 plan	866	$8.06	7K	4.6%	Form 4
Dec 6, 2024	Yat Sun Or Chief Scientific Officer	Sold10b5-1 plan	2,591	$8.06	21K	0.7%	Form 4
Dec 6, 2024	Paul J Mellett Chief Fin. & Admin Officer	Sold10b5-1 plan	2,591	$8.06	21K	2.7%	Form 4
Dec 6, 2024	Jay R. Luly President and CEO	Sold10b5-1 plan	5,142	$8.06	41K	0.6%	Form 4

Dec 5, 2025No plan
Kathleen S. Capps
See Remarks · sold 323 at $14.23
5K
3.7% of stake
Dec 5, 2025No plan
Harry R. Trout III
See Remarks · sold 542 at $14.23
8K
3.2% of stake
Dec 5, 2025No plan
Scott T. Rottinghaus
Chief Medical Officer · sold 798 at $14.23
11K
3.5% of stake
Dec 5, 2025No plan
Brendan Luu
Chief Business Officer · sold 1,394 at $14.23
20K
3.5% of stake
Dec 5, 2025No plan
Tara Lynn Kieffer
Chief Product Strategy Officer · sold 2,106 at $14.23
30K
6.4% of stake
Dec 5, 2025No plan
Yat Sun Or
Chief Scientific Officer · sold 2,390 at $14.23
34K
0.6% of stake
Dec 5, 2025No plan
Jay R. Luly
President and CEO · sold 4,743 at $14.23
67K
0.5% of stake
Dec 2, 2025No plan
Kathleen S. Capps
See Remarks · sold 207 at $13.96
3K
2.3% of stake
Dec 2, 2025No plan
Harry R. Trout III
See Remarks · sold 380 at $13.96
5K
2.2% of stake
Feb 12, 2025
Jay R. Luly
President and CEO · bought 45,000 at $5.69
256K
5.6% of stake
Dec 6, 202410b5-1 plan
Tara Lynn Kieffer
Chief Product Strategy Officer · sold 2,283 at $8.06
18K
7.2% of stake
Dec 6, 202410b5-1 plan
Brendan Luu
Chief Business Officer · sold 2,283 at $8.06
18K
6.0% of stake
Dec 6, 202410b5-1 plan
Scott T. Rottinghaus
Chief Medical Officer · sold 866 at $8.06
7K
4.6% of stake
Dec 6, 202410b5-1 plan
Yat Sun Or
Chief Scientific Officer · sold 2,591 at $8.06
21K
0.7% of stake
Dec 6, 202410b5-1 plan
Paul J Mellett
Chief Fin. & Admin Officer · sold 2,591 at $8.06
21K
2.7% of stake
Dec 6, 202410b5-1 plan
Jay R. Luly
President and CEO · sold 5,142 at $8.06
41K
0.6% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ENTA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ENTA

CompareIntrinsic value

FBIOFortress Biotech Inc.

$1.97+1.55%59

XLOXilio Therapeutics, Inc.

$8.71+0.35%40

RMTIRockwell Medical, Inc.

$8.05-0.49%37

DERMJourney Medical Corp

$4.73+1.94%25

BCYCBicycle Therapeutics PLC

$3.72+1.36%40

LXRXLexicon Pharmaceuticals, Inc.

$1.48+1.37%40

VRDNViridian Therapeutics Inc.

$29.06+15.53%40

ASMBAssembly Biosciences Inc.

$19.87-0.25%19

Held by ETFs

ENTA is in 13 US ETFs. The largest of them, with ENTA's weight in each:

Spot a number that looks wrong? Check it in ENTA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ENTA

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.